Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy

Journal of Young Pharmacists

Volumn 5, Issue 1, 2013, Pages 13-17

  Kumar, Dhakchinamoorthi Krishna ^a   Shewade, Deepak Gopal ^a   Parasuraman, Subramani ^a   Rajan, Sundaram ^a   Balachander, Jayaraman ^a   Chandran, B V Sai ^a   Adithan, Chandrasekaran ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

7 Hydroxy warfarin; Carbamazepine; Metabolic ratio; Plasma concentration; Warfarin

Indexed keywords

2 PROPANOL; 7 HYDROXY WARFARIN; BUFFER; CARBAMAZEPINE; DRUG METABOLITE; POTASSIUM DIHYDROGEN PHOSPHATE; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ANALYTICAL PARAMETERS; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG RETENTION; FEMALE; HUMAN; LIMIT OF DETECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC RATIO; PATIENT CODING; PRIORITY JOURNAL; RELIABILITY; RETENTION TIME; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; VENOUS BLOOD;

EID: 84882425683     PISSN: 09751483     EISSN: 09751505     Source Type: Journal    
DOI: 10.1016/j.jyp.2013.02.001     Document Type: Article

References (24)

1. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:513-548.
2. Salem DN, O'Gara PT, Madias C, Pauker SG. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:593-629.
3. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:429-456.
4. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348:423-428.
5. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315-328.
6. Horowitz B, Minor P, Morgenthaler JJ, et al. WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser. 2004;924:1-232.
7. Anthony CJ, Karim S, Ackroyd-Stolarz S, et al. Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department. Ann Pharmacother. 2011;45:881-887.
8. Ghambari H, Hadjmohammadi M. Low-density solvent-based dispersive liquideliquid microextraction followed by high performance liquid chromatography for determination of warfarin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;899:66-71.
9. Miura M, Okuyama S, Kato S, et al. Simultaneous determination of warfarin and 7-hydroxywarfarin enantiomers by high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit. 2011;33:108-114.
10. Kwon MJ, Kim HJ, Kim JW, et al. Determination of plasma warfarin concentrations in Korean patients and its potential for clinical application. Korean J Lab Med. 2009;29:515-523.
11. Sun S, Wang M, Su L, Li J, Li H, Gu D. Study on warfarin plasma concentration and its correlation with international normalized ratio. J Pharm Biomed Anal. 2006;42:218-222.
12. Lombardi R, Chantarangkul V, Cattaneo M, Tripodi A. Measurement of warfarin in plasma by high performance liquid chromatography (HPLC) and its correlation with the international normalized ratio. Thromb Res. 2003;111:281-284.
13. Kulkarni UP, Swar BD, Karnad DR, et al. A pilot study of the association of pharmacokinetic and pharmacodynamic parameters of warfarin with the dose in patients on long-term anticoagulation. Br J Clin Pharmacol. 2008;65: 787-790.
14. Huang C, Yang J, Du Y, Miao L. Measurement of free concentrations of highly protein-bound warfarin in plasma by ultra-performance liquid chromatographyetandem mass spectrometry and its correlation with the international normalized ratio. Clinica Chimica Acta. 2008;393:85-89.
15. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007;121:23-34.
16. Zhang Z, Fasco MJ, Huang Z, Guengerich FP, Kaminsky LS. Human cytochromes P450 1A1 and 1A2: R-warfarin as a probe. Drug Metab Dispos. 1995;23:1339-1345.
17. Locatelli I, Kmetec V, Mrhar A, Grabnar I. Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;818:191-198.
18. Fasco MJ, Piper LJ, Kaminsky LS. Biochemical applications of a quantitative high-pressure liquid chromatographic assay of warfarin and its metabolites. J Chromatogr. 1977;131:365-373.
19. George M, Shewade DG, Kumar SV, Adithan C. Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug. Indian J Pharmacol. 2012;44:485-488.
20. Subraja K, Dkhar SA, Priyadharsini R, et al. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Eur J Clin Pharmacol; 2012;. http://dx.doi.org/10.1007/s00228-012-1381-8.
21. Baca QJ, Golan DE. Pharmacokinetics. In: Golan DE, Tashjian AH, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA, Rose HS, eds. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Philadelphia: Lippincott Williams & Wilkins, Wolters Kluwer; 2012:27-42.
22. Namazi S, Azarpira N, Hendijani F, Khorshid MB, Vessal G, Mehdipour AR. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: A cross-sectional study in Iran. Clin Ther. 2010;32:1050-1060.
23. Herman D, Locatelli I, Grabnar I, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 2005;5:193-202.
24. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994;4:39-42.